Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
1.
Arch Rheumatol ; 35(2): 163-169, 2020 Jun.
Article in English | MEDLINE | ID: mdl-32851364

ABSTRACT

OBJECTIVES: This study aims to investigate the factors associated with early discontinuation (within one year) of etanercept (ETA) in rheumatoid arthritis (RA) patients who began ETA as first biologic disease-modifying antirheumatic drug (bDMARD) and who were entered into the Gruppo Italiano di Studio sulla Early Arthritis (Italian Group for the Study of Early Arthritis; GISEA) registry. PATIENTS AND METHODS: This registry-based cohort study included 477 RA patients (95 males, 382 females; median age 53 years; range 18 to 83 years) who began ETA as first bDMARD. Patient demographics, disease features and drugs were re-evaluated after 12 months. Baseline predictors of ETA discontinuation were estimated by univariate and multivariate analyses using Cox regression model. RESULTS: Seventy patients (14.7%) discontinued ETA during the first year (for inefficacy in 55.8%, adverse events in 28.6%, and other reasons in 6.5%). Concurrent conventional synthetic DMARDs (csDMARDs) were reported in 54.3% of patients, mainly methotrexate (MTX), while 52.4% of subjects took low doses of glucocorticoids. Patients stopping ETA more frequently showed one or more comorbidities, mainly cardiovascular diseases (28.6% vs. 15.7% in patients stopping and continuing ETA, respectively, p=0.009). The presence of comorbidities and a combination therapy with csDMARDs other than MTX were independent factors associated with early discontinuation of ETA at multivariate Cox analysis. CONCLUSION: Although ETA demonstrated a high persistence in biologic-naïve RA patients, about 15% of patients discontinued the treatment within 12 months. The presence of comorbidities and a combination therapy with csDMARDs other than MTX were the main factors for an early withdrawal of the drug.

2.
J Clin Med ; 9(1)2020 Jan 19.
Article in English | MEDLINE | ID: mdl-31963908

ABSTRACT

BACKGROUND: Treatment of rheumatoid arthritis (RA)-related interstitial lung disease (ILD) is challenging, and many conventional and biologic disease-modifying anti-rheumatic drugs (DMARDs) have been associated with ILD development or progression. The aim of this multicentric retrospective study was to analyze the evolution of ILD in Italian RA-ILD patients treated with abatacept (ABA). METHODS: All RA-ILD patients treated with ABA for at least six months were retrospectively evaluated. Serology, previous and concurrent therapies, chest high-resolution computer tomography (HRCT), forced vital capacity (FVC), and lung diffusion of carbon monoxide (CO, DLCO) were collected. RESULTS: Forty-four patients were included; HRCT, FVC, and DLCO were analyzed at baseline, at one year, and at the end of follow-up. A remission or a low disease activity of RA was reached in 41/44 patients. Overall, FVC and DLCO remained stable or increased in 86.1% and 91.7% of patients, respectively, while HRCT was stable or improved in 81.4% of them. Previous and concurrent treatments, in particular, methotrexate, serology, age, sex, joint and lung disease duration were not associated with the outcome at univariate analysis. CONCLUSION: The management of RA-ILD patients remains a critical unmet medical need. Waiting for prospective controlled studies, ABA has shown a good safety profile in our cohort of Italian RA-ILD patients.

4.
Clin Exp Rheumatol ; 35(1): 93-97, 2017.
Article in English | MEDLINE | ID: mdl-27974094

ABSTRACT

OBJECTIVES: The aim of the study was to retrospectively evaluate the long-term safety profile of anti-tumour necrosis factor (TNF)-α agents on the liver of patients with spondyloarthritis (SpA) and a previously resolved hepatitis B virus (HBV) infection. METHODS: Medical records from 992 consecutive outpatients receiving anti-TNF-α therapy between 2007 and 2015 were retrospectively reviewed. HBV infection was assessed evaluating HBV surface antigen (HBsAg), antibodies to HBsAg (anti-HBs), antibodies to hepatitis B core (anti-HBc), and HBV-DNA levels. In patients with a previously resolved HBV infection, serum levels of aminotransferase (AST/ALT) were also assessed every three months, while HBsAg and HBV-DNA every six months. RESULTS: We identified 131 consecutive patients (70 males, 61 females) with SpA and resolved HBV infection. At baseline none of the patients were positive for HBV-DNA, and AST/ALT levels were within the normal range with no subsequent increase during the observational treatment period. None received antiviral therapy prior to or during anti-TNF drug administration. At the end of the follow-up period (75.50±33.37 months) no viral reactivation was observed in anti-HBc positive patients, regardless of anti-HBs positivity. During the whole follow-up, HBV-DNA was undetectable in all patients, HBsAg remained negative, and it was not necessary to discontinue biologic therapy because of liver damage. CONCLUSIONS: Our results confirm that pre-emptive antiviral prophylaxis may not be necessary routine, but strict monitoring for AST/ALT levels, as well as for changes in HBV serology and HBV-DNA remain necessary and seem a realistic and cost-effective approach to identify early viral reactivation.


Subject(s)
Antirheumatic Agents/therapeutic use , Biological Products/therapeutic use , Hepatitis B/complications , Liver/drug effects , Spondylarthritis/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Aged , Alanine Transaminase/blood , Antirheumatic Agents/pharmacology , Biological Products/pharmacology , Female , Hepatitis B/blood , Humans , Male , Middle Aged , Retrospective Studies , Spondylarthritis/blood , Spondylarthritis/complications , Virus Activation/drug effects
5.
Arthritis Care Res (Hoboken) ; 69(7): 966-972, 2017 07.
Article in English | MEDLINE | ID: mdl-27723261

ABSTRACT

OBJECTIVE: To perform a cost-effectiveness analysis of mud-bath therapy (MBT) in addition to usual treatment compared to usual treatment alone in patients with bilateral knee osteoarthritis (OA). METHODS: An economic evaluation alongside a randomized controlled trial was conducted. Patients were randomly assigned to receive either a 2-week cycle of MBT in addition to their usual treatment or to continue routine care alone. The EuroQol 5-domain questionnaire was administered at baseline, 2 weeks, and at 3, 6, 9, and 12 months. Direct health care resource consumption data up until 12 months were derived from a daily diary given to patients and returned at prescheduled followup visits. RESULTS: A total of 103 patients were included (n = 53 for MBT patients; n = 50 for controls). Overall, patients in the MBT group accrued mean ± SD 0.835 ± 0.10 quality-adjusted life years (QALYs) compared to 0.753 ± 0.11 in the control group (P < 0.001). Average direct costs per patient (€303 versus €975; P < 0.001) were higher in the control group, primarily because of hospitalization for total knee replacement and use of intraarticular hyaluronic acid. Bootstrapping replications of costs and QALY sample distributions consistently indicated that the MBT therapy combined with standard therapy represents a dominant strategy as compared with standard therapy alone. The probability of MBT being cost-effective at standard cost-effectiveness thresholds (e.g., €20,000/QALY) is 100%. CONCLUSION: The results of this cost-effectiveness analysis support the use of MBT as midterm complementary therapy in the management of knee OA.


Subject(s)
Cost-Benefit Analysis , Mud Therapy/economics , Osteoarthritis, Knee/economics , Osteoarthritis, Knee/therapy , Patient Care/economics , Adult , Aged , Aged, 80 and over , Combined Modality Therapy/economics , Combined Modality Therapy/methods , Cost-Benefit Analysis/methods , Female , Follow-Up Studies , Humans , Male , Middle Aged , Mud Therapy/methods , Osteoarthritis, Knee/diagnosis , Patient Care/methods , Prospective Studies , Single-Blind Method
6.
Int J Biometeorol ; 59(11): 1691-700, 2015 Nov.
Article in English | MEDLINE | ID: mdl-25750093

ABSTRACT

Adipocytokines, including adiponectin, resistin, and visfatin may play an important role in the pathophysiology of osteoarthritis (OA). Spa therapy is one of the most commonly used non-pharmacological approaches for OA, but its mechanisms of action are not completely known. The aim of the present study was to assess whether a cycle of mud-bath therapy (MBT) influences the serum levels of adiponectin, resistin, and visfatin in patients with knee OA. As part of a prospective randomized, single blind-controlled trial evaluating the efficacy of MBT in knee OA, we included in this study 95 outpatients. One group (n = 49) received a cycle of MBT at the spa center of Chianciano Terme (Italy) in addition to the usual treatment, and one group (control group; n = 46) continued their regular care routine alone. Patients were assessed at basal time and at the end of the study (15 days) for clinical and biochemical parameters. Clinical assessments included spontaneous pain on a visual analog scale (VAS) score and the Western Ontario and McMaster Universities index (WOMAC) subscores for knee OA evaluated as total pain score (W-TPS), total stiffness score (W-TSS), and total physical function score (W-TPFS). Adiponectin, resistin and visfatin serum levels were assessed by enzyme immunoassay methods. At the end of the mud-bath therapy, serum adiponectin levels showed a significant decrease (p < 0.001), while no significant modifications were found in the control group at day 15. Serum resistin showed a significant decrease (p < 0.0001) in the MBT group at the end of the study and a significant increase in the control patients (p < 0.001). No significant modifications of visfatin were found in MBT. Furthermore, we tested the relationships between demographic and clinical parameters and adipocytokine concentrations measured in the MBT group at basal and at the end of the study. In conclusion, the present study shows that a cycle of MBT can modify serum levels of adiponectin and resistin but not the circulating levels of visfatin. In view of the recent evidences about the involvement of adiponectin and resistin in the pathogenesis and progression of OA, the decrease of these adipokines after mud-bath therapy may play a protective role in the course of the disease. However, it remains to be clarified which of the mechanisms of action of MBT may have determined the changes in serum levels of adiponectin and resistin that we observed.


Subject(s)
Adiponectin/blood , Cytokines/blood , Mud Therapy , Nicotinamide Phosphoribosyltransferase/blood , Osteoarthritis, Knee/therapy , Resistin/blood , Aged , Aged, 80 and over , Body Mass Index , Cholesterol/blood , Female , Humans , Male , Middle Aged , Osteoarthritis, Knee/blood , Triglycerides/blood
7.
Int J Biometeorol ; 59(7): 783-9, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25194752

ABSTRACT

Obesity is a major risk factor for arterial hypertension, coronary artery disease, dyslipidemias, and type 2 diabetes. Spa therapy has long been used for treating obesity and its comorbidities. Enlargement of adipose tissue has been linked to a dysregulation of adipokine secretion and adipose tissue inflammation. Adipokines are currently investigated as potential drug targets in these conditions. Our primary aim was to assess the clinical efficacy of a 3-week program of diet combined with spa therapy in obese patients with and without type 2 diabetes. The secondary aim was to examine whether this combined program influences the response of serum levels of leptin, adiponectin, visfatin, and high-sensitivity C-reactive protein. Fifty obese males were enrolled and 21 of these featured a type 2 diabetes. During the 3-week period of the study, the patients were on a 1,000-kcal diet and were involved in mineral bath and total body's mud-pack applications (15 procedures). Patients were assessed at baseline and at the end of the therapy for clinical and biochemical parameters (total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, glycemia, and adipokines). We showed that a 3-week program of spa therapy in obese patients induced significant decrease of body weight, body mass index, triglycerides, total cholesterol, low-density lipoprotein (LDL) cholesterol, glycemia, and serum levels of leptin and high-sensitivity C-reactive protein. So, a cycle of mud-bath therapy associated with a controlled diet may be a promising treatment for obesity and type 2 diabetes decreasing body weight and many risk factors for atherosclerosis and metabolic syndrome.


Subject(s)
Balneology , Diabetes Mellitus, Type 2/therapy , Diet , Obesity/therapy , Adiponectin/blood , Adult , Aged , C-Reactive Protein/analysis , Cytokines/blood , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/diet therapy , Humans , Leptin/blood , Male , Middle Aged , Nicotinamide Phosphoribosyltransferase/blood , Obesity/blood , Obesity/diet therapy , Pilot Projects , Treatment Outcome
8.
Clin Rheumatol ; 33(2): 273-6, 2014 Feb.
Article in English | MEDLINE | ID: mdl-23975363

ABSTRACT

Psoriatic arthritis (PsA) is an inflammatory arthropathy associated with skin and/or nail psoriasis. TNF-α, in addition to its pro-inflammatory role, is an essential cytokine for the host's defense, and its depletion by treatment may facilitate the risk of viral infections or their reactivation. The aim of this study was to evaluate the efficacy and safety of TNF-α blockers in PsA patients with concurrent hepatitis C virus (HCV) infection. This is a multicenter study carried out in four Italian centers specialized in the diagnosis and treatment of PsA. At baseline and after 6 (T6) and 12 months (T12) of therapy, data concerning PsA activity and liver tests were registered. A total of 15 PsA patients with concomitant HCV infection were included in the study. At baseline, 13 patients had low viral load, and liver enzyme tests were within the normal range. During the observation period, these values remained stable. On the other hand, at baseline, a high viral load with slightly increased values of AST and ALT was detected in one patient. At T6 and T12, these values decreased. The remaining patient, at baseline, had low viral load, but with slightly increased AST and ALT values that normalized during the observation period. This is the greatest sample size available in the literature on this topic. The data suggests that anti-TNF-α agents are effective and safe in PsA patients with concomitant HCV. We suggest that the use of anti-TNF-α agents, accompanied by close monitoring, could be a therapeutic option.


Subject(s)
Antirheumatic Agents/therapeutic use , Arthritis, Psoriatic/complications , Arthritis, Psoriatic/drug therapy , Hepatitis C/complications , Hepatitis C/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adalimumab , Aged , Alanine Transaminase/blood , Antibodies, Monoclonal, Humanized/therapeutic use , Aspartate Aminotransferases/blood , Biological Products/therapeutic use , Etanercept , Female , Humans , Immunoglobulin G/therapeutic use , Inflammation , Male , Middle Aged , Receptors, Tumor Necrosis Factor/therapeutic use , Retrospective Studies , Time Factors , Viral Load
9.
Int J Biometeorol ; 58(1): 79-86, 2014 Jan.
Article in English | MEDLINE | ID: mdl-23314489

ABSTRACT

The aim of this study was to evaluate both the short-term and the long-term effectiveness of spa therapy in patients with primary hand osteoarthritis (OA). This was a prospective randomized, single blind controlled trial. Sixty outpatients with primary bilateral hand OA were included in the study and randomized to one of two groups. One group (n = 30) was treated with 12 daily local mud packs and generalized thermal baths with a sulfate-calcium-magnesium-fluorides mineral water added to usual treatment. The control group (n = 30) continued regular outpatient care routine (exercise, NSAIDs and/or analgesics). Each patient was examined at baseline, after 2 weeks, and after 3, 6, 9 and 12 months. Primary outcome measures were global spontaneous hand pain on a visual analogue scale (VAS) and the functional index for hand osteoarthritis (FIHOA) score; secondary outcomes were health assessment questionnaire (HAQ), duration of morning stiffness, medical outcomes study 36-item short form (SF-36) and symptomatic drugs consumption. Our results demonstrated that the efficacy of spa therapy was significant in all the assessed parameters, both at the end of therapy and after 3 months; the values of FIHOA, HAQ and drugs consumption continued to be significantly better after 6 months in comparison with baseline. There were no significant modifications of the parameters throughout the follow-up in the control group. Differences between the two groups were significant for all parameters at the 15th day and at 3 months follow-up; regarding FIHOA, HAQ, and symptomatic drugs consumption, the difference between the two groups persisted and was significant at 6month follow-up. Tolerability of spa therapy seemed to be good. In conclusion, our results confirm that the beneficial effects of spa therapy in patients with hand OA last over time.


Subject(s)
Mineral Waters/therapeutic use , Mud Therapy , Osteoarthritis/therapy , Aged , Baths , Calcium/therapeutic use , Female , Fluorides/therapeutic use , Hand , Humans , Magnesium/therapeutic use , Male , Middle Aged , Single-Blind Method , Sulfates/therapeutic use , Treatment Outcome
12.
Mod Rheumatol ; 22(5): 758-65, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22245976

ABSTRACT

OBJECTIVES: To translate the functional index for hand osteoarthritis (FIHOA) into Italian and to evaluate its reliability and validity in Italian patients with hand osteoarthritis (HOA). METHODS: The original French FIHOA was translated into Italian according to the guidelines for cross-cultural adaptation and then administered to 72 outpatients with HOA, together with the visual analogue scale of pain (VAS), the Health Assessment Questionnaire (HAQ) and the Short Form Health Survey (SF-36). Test-retest reliability was verified by having all patients fill out the Italian version of FIHOA again 1 week later. Item-item analysis was performed. The Wilcoxon signed-rank test and Spearman's rank correlation coefficient were calculated to compare test and retest responses and to evaluate the degree of correlation. Internal consistency reliability was evaluated by Cronbach's alpha coefficient, and internal structure validity was appraised through factor analysis, also taking a varimax rotation into consideration. Construct validity was assessed by correlating FIHOA with other measures of functional impairment and pain using Spearman's rank correlation coefficient. RESULTS: Internal consistency was high (Cronbach's α = 0.87). Test-retest reliability showed a Spearman's rho of 0.942 (p < 0.001). A significant correlation (p < 0.001) between FIHOA, VAS and HAQ and a significant negative correlation between FIHOA and SF-36 subscales were observed. FIHOA was confirmed to be a non-unidimensional scale, but in addition to the total score of the index, three subtotals of item scores were considered to provide better evaluations of finger functionality (items 3, 6, 8 and 10), wrist functionality (items 2 and 7) and hand strength (items 4 and 5) in single individuals. CONCLUSIONS: The Italian version of FIHOA is a reliable and valid instrument for evaluating functional disability in Italian-speaking HOA patients.


Subject(s)
Cross-Cultural Comparison , Hand Joints/physiopathology , Osteoarthritis/physiopathology , Pain Measurement/methods , Pain/physiopathology , Activities of Daily Living , Adult , Aged , Cross-Sectional Studies , Disability Evaluation , Female , Functional Laterality , Hand Joints/diagnostic imaging , Health Status , Humans , Italy , Male , Middle Aged , Osteoarthritis/complications , Osteoarthritis/diagnostic imaging , Pain/diagnostic imaging , Pain/etiology , Radiography , Reproducibility of Results , Severity of Illness Index , Surveys and Questionnaires
13.
Int J Biometeorol ; 56(4): 583-90, 2012 Jul.
Article in English | MEDLINE | ID: mdl-21573819

ABSTRACT

The aims of this study were to evaluate whether balneotherapy with mineral sulphate-bicarbonate-calcium water could determine substantial symptomatic improvement, and to detect any changes in the quality of life (QoL) of patients with symptomatic knee osteoarthritis (OA). This was a prospective randomized, single blind controlled trial. Sixty outpatients with primary bilateral knee OA, according to ACR criteria, were included in the study and randomized to one of two groups: group I (30 patients) was treated with a daily sulphate-bicarbonate-calcium mineral water bath; group II (30 patients), the control group, continued their regular outpatient care routine. At baseline, after 15 days and after 12 weeks, patients were evaluated by Visual Analogue Scale (VAS) for spontaneous pain, Lequesne and Womac Index for gonarthrosis, SF-36, Arthritis Impact Measurement Scale (AIMS) and symptomatic drugs consumption. We observed a significant improvement of all parameters at the end of the cycle of balneotherapy which persisted throughout the follow-up period, whereas in the control group no significant differences were noted. This symptomatic effect was confirmed by the significant reduction of symptomatic drugs consumption. The differences between the two groups were significant for all considered parameters already from the 15th day and persisted during follow-up. Tolerability of balneotherapy seemed to be good, with light and transitory side effects. Our results confirm that the beneficial effects of balneotherapy in patients with knee OA last over time, with positive effects on the painful symptomatology, a significant improvement on functional capacities and QoL. Balneotherapy can represent a useful backup to pharmacological treatment of knee OA or a valid alternative for patients who do not tolerate pharmacological treatments.


Subject(s)
Balneology , Osteoarthritis, Knee/therapy , Aged , Female , Humans , Male , Middle Aged , Osteoarthritis, Knee/physiopathology , Pain Management , Quality of Life , Treatment Outcome
16.
Hum Immunol ; 71(2): 206-11, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19931339

ABSTRACT

miRNAs have recently emerged as key regulators of the immune system, being involved in lymphocyte selection and proliferation, in T(reg) cells differentiation, and in hematopoiesis in general. Rheumatoid arthritis (RA) is an autoimmune pathology the etiology of which is still obscure. Although a multifactorial pathogenesis has been hypothesized, the precise mechanisms leading to the disease are still poorly understood at the molecular level. miRNA expression profile analysis highlighted that miR-223 is the only miRNA that is strikingly deregulated in peripheral T-lymphocytes from RA patients compared with healthy donors. Further analysis by quantitative reverse transcription-polymerase chain analysis confirmed that miR-223 is overexpressed in T-lymphocytes from RA patients (n = 28) compared with healthy donors (n = 10). Moreover, purification of different T-lymphocyte populations from RA patients highlights that miR-223 is expressed at higher levels in naive CD4(+) lymphocytes, whereas its expression is barely detectable in T(h)-17 cells. In summary, our data provide a first characterization of the miRNA expression profiles of peripheral T-lymphocytes of RA patients, identifying miR-223 as overexpressed in CD4(+) naive T-lymphocytes from these individuals. A deeper analysis of the biologic functions and effects of the expression of miR-223 in T-lymphocytes is needed to clarify the exact link between our observation and the disease.


Subject(s)
Arthritis, Rheumatoid/genetics , Gene Expression Profiling , MicroRNAs/biosynthesis , T-Lymphocyte Subsets/immunology , T-Lymphocytes/immunology , Adult , Aged , Aged, 80 and over , Female , Gene Expression , Humans , Male , MicroRNAs/genetics , MicroRNAs/immunology , Middle Aged , Oligonucleotide Array Sequence Analysis , RNA, Messenger/analysis , Reverse Transcriptase Polymerase Chain Reaction , Up-Regulation , Young Adult
17.
Expert Opin Pharmacother ; 10(4): 579-87, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19284361

ABSTRACT

BACKGROUND: The poor prognosis of rheumatoid arthritis (RA) can be aggravated by the concomitant presence of chronic hepatitis C virus (HCV) infection and there are no guidelines for the treatment of patients affected by both conditions. OBJECTIVE: To propose new therapeutic strategies for patient affected by RA and concomitant HCV chronic infection. METHODS: Review of the literature on the usage of cyclosporine-A (CsA) and anti-tumour-necrosis-factor (TNF)-alpha agents for the treatment of patients affected by RA and HCV. RESULTS/CONCLUSION: CsA exerts an inhibitory effect on HCV replication and it is safe in patients affected by RA and HCV. Anti-TNF-alpha agents are safe and efficacious in patient with RA and HCV. Anti-TNF-alpha and CsA can be safely given in combination in RA patients with HCV infection.


Subject(s)
Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Cyclosporine/therapeutic use , Hepatitis C, Chronic/drug therapy , Immunosuppressive Agents/therapeutic use , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Arthritis, Rheumatoid/complications , Arthritis, Rheumatoid/pathology , Drug Therapy, Combination , Hepatitis C, Chronic/complications , Hepatitis C, Chronic/pathology , Humans , Prognosis , Receptors, Tumor Necrosis Factor/therapeutic use , Treatment Outcome
18.
Autoimmun Rev ; 8(2): 100-3, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18694850

ABSTRACT

A wide variety of rheumatic diseases has been documented in the presence of hepatitis C virus (HCV) infection and in human immunodeficiency virus (HIV) infection. In this conditions, physicians are refrained from using corticosteroids and/or immunosuppressants agents because of the risk of favouring viral replication and the progression of the underlying viral disease. In the present review we have focused our attention on the possible role of cyclosporine A (CsA), anti-Tumour Necrosis Factor (TNF) alpha agents in the treatment of HIV or HCV infected autoimmune patients. The results drown from the literature and from our personal experience confirm the safety of CsA and anti-TNF alpha agents, in terms of viral load and liver toxicity. A limited experience also suggest that both therapies can be given in combination in rheumatoid arthritis patients without increasing the risk of adverse events.


Subject(s)
Antibodies/therapeutic use , Cyclosporine/therapeutic use , HIV Infections/complications , Hepatitis C, Chronic/complications , Rheumatic Diseases/drug therapy , Cyclosporine/administration & dosage , Humans , Rheumatic Diseases/complications , Rheumatic Diseases/immunology , Tumor Necrosis Factor-alpha/immunology , Tumor Necrosis Factor-alpha/metabolism
19.
Ann N Y Acad Sci ; 1110: 544-9, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17911470

ABSTRACT

Because of the relatively high prevalence of both hepatitis C virus (HCV) infection and autoimmune disorders (ADs), it is not rare to encounter in daily clinical practice patients with ADs also carrying HCV. Corticosteroids and/or immunosuppressant drugs are needed to treat ADs, but they place HCV-infected patients at risk of worsening the infection. So, rheumatologists have often refrained from using corticosteroids or immunosuppressants in AD when HCV-RNA is also present. Cyclosporin A (CsA) is an immunosuppressive agent used to treat a wide range of ADs, but there is a large evidences in the literature, both in vitro and in vivo, suggesting that CsA also exerts an inhibitory effect on HCV replication at standard therapeutic dose. Therefore, this evidence has opened new ways to improve the therapy and the prognosis in patients with HCV-related liver diseases, including those with transplants. Recent reports, although limited in number, also suggest the safety of CsA in the treatment of patients with AD and concomitant HCV infection. In this review we also report our personal experience on the combination treatment with CsA and anti-TNF-alpha agents in rheumatoid arthritis.


Subject(s)
Cyclosporine/therapeutic use , Drug-Related Side Effects and Adverse Reactions , Hepatitis C/complications , Hepatitis C/drug therapy , Rheumatic Diseases/complications , Rheumatic Diseases/drug therapy , Autoimmune Diseases/drug therapy , Autoimmune Diseases/metabolism , Chronic Disease , Cyclosporine/adverse effects , Hepatitis C/metabolism , Hepatitis C/virology , Humans , Rheumatic Diseases/metabolism , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/metabolism
20.
Rheumatol Int ; 27(6): 523-9, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17106661

ABSTRACT

Spa therapy and short wave therapy are two of the most commonly used non-pharmacological approaches for osteoarthritis. The aim of this study was to assess their efficacy in comparison to conventional therapy in patients with osteoarthritis of the knee in a single blind, randomized, controlled trial. Seventy-four outpatients were enrolled; 30 patients were treated with a combination of daily local mud packs and arsenical ferruginous mineral bath water from the thermal resort of Levico Terme (Trento, Italy) for 3 weeks; 24 patients were treated with short wave therapy for the same period and 20 patients continued regular, routine ambulatory care. Patients were assessed at baseline, upon completion of the 3-week treatment period, and 12 weeks later. Spa therapy and short wave therapy both demonstrated effective symptomatic treatment in osteoarthritis of the knee at the end of the treatment, but only the spa therapy was shown to have efficacy persistent over time. Our study demonstrated the superiority of arsenical ferruginous spa therapy compared to short wave therapy in the treatment of osteoarthritis of the knee, probably in relationship to the specific effects of the minerals in this water.


Subject(s)
Balneology , Mud Therapy , Osteoarthritis, Knee/therapy , Acetaminophen/administration & dosage , Aged , Analgesics, Non-Narcotic/administration & dosage , Arsenicals , Female , Ferrous Compounds , Humans , Male , Middle Aged , Osteoarthritis, Knee/drug therapy , Patient Satisfaction , Severity of Illness Index , Single-Blind Method , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...